Mucosal Vaccination against Tuberculosis Using Inert Bioparticles
Open Access
- 1 November 2013
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 81 (11) , 4071-4080
Abstract
Needle-free, mucosal immunization is a highly desirable strategy for vaccination against many pathogens, especially those entering through the respiratory mucosa, such as Mycobacterium tuberculosis . Unfortunately, mucosal vaccination against tuberculosis (TB) is impeded by a lack of suitable adjuvants and/or delivery platforms that could induce a protective immune response in humans. Here, we report on a novel biotechnological approach for mucosal vaccination against TB that overcomes some of the current limitations. This is achieved by coating protective TB antigens onto the surface of inert bacterial spores, which are then delivered to the respiratory tract. Our data showed that mice immunized nasally with coated spores developed humoral and cellular immune responses and multifunctional T cells and, most importantly, presented significantly reduced bacterial loads in their lungs and spleens following pathogenic challenge. We conclude that this new vaccine delivery platform merits further development as a mucosal vaccine for TB and possibly also other respiratory pathogens.Keywords
This publication has 37 references indexed in Scilit:
- Immune-Complex Mimics as a Molecular Platform for Adjuvant-Free Vaccine DeliveryPLOS ONE, 2013
- Efficacy, heat stability and safety of intranasally administered Bacillus subtilis spore or vegetative cell vaccines expressing tetanus toxin fragment CVaccine, 2010
- Mucosal delivery of antigens using adsorption to bacterial sporesVaccine, 2010
- Bacillus subtilis isolated from the human gastrointestinal tractResearch in Microbiology, 2009
- Inhaled nanoparticles—A current reviewInternational Journal of Pharmaceutics, 2008
- Should a new tuberculosis vaccine be administered intranasally?Tuberculosis, 2007
- The role of antibody-mediated immunity in defense against Mycobacterium tuberculosis: Advances toward a novel vaccine strategyTuberculosis, 2006
- A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab′)2 fragment prolong survival of mice infected withMycobacterium tuberculosisClinical and Experimental Immunology, 2004
- Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cellsVirology, 2004
- A novel TB vaccine; towards a strategy based on our understanding of BCG failureVaccine, 2002